Literature DB >> 16042992

The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.

Roy Zaltzman1, Alexander Alexandrovich, Victoria Trembovler, Esther Shohami, Illana Gozes.   

Abstract

A single administration of the neuroprotective peptide NAP was previously shown to protect against death associated with closed head injury (CHI) and enhance recovery of the surviving mice. The protective effect was accompanied by down-regulation of the relative mRNA content of the complement receptor 3 (Mac-1, a marker for inflammation) as measured about a month after the injury. In contrast, the mRNA transcripts for activity-dependent neuroprotective protein (ADNP, the NAP containing protein) were shown to increase 29 days post CHI in the injured hemisphere of Mac-1 expressing mice. The present study was set out to investigate: (1) are Mac-1-deficient mice less susceptible to the adverse outcome of traumatic head injury; (2) does NAP treatment affect Mac-1-deficient mice subjected to head injury; and (3) is Mac-1 expression associated with ADNP expression. Results showed that (1) Mac-1-deficient mice were partially protected against death associated with severe head injury as compared to Mac-1 expressing mice. (2) Significant protection against death was observed in NAP-treated mice and an increase in recovery was observed in the NAP-treated Mac-1 mice 4 weeks after injury. (3) ADNP expression did not change in the Mac-1-deficient mice following head injury. Our working hypothesis is that a month following injury, gene expression in the injured brain is altered and competing proteins are expressed such as Mac-1 that is associated with inflammation and ADNP that is associated with neuroprotection. Obviously, this plasticity in gene expression is intimately interwoven with the genetic background of the animal. NAP treatment tilts the balance toward neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042992     DOI: 10.1016/j.peptides.2005.03.014

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.

Authors:  Rafael Fernandez-Montesinos; Manuel Torres; David Baglietto-Vargas; Antonia Gutierrez; Illana Gozes; Javier Vitorica; David Pozo
Journal:  J Mol Neurosci       Date:  2009-10-21       Impact factor: 3.444

2.  Activity-dependent neuroprotective protein modulates its own gene expression.

Authors:  Moutasem S Aboonq; Sylvia A Vasiliou; Kate Haddley; John P Quinn; Vivien J Bubb
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

3.  Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death.

Authors:  Soraya Scuderi; Agata Grazia D'Amico; Alessandro Castorina; Concetta Federico; Giuseppina Marrazzo; Filippo Drago; Claudio Bucolo; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2014-02-02       Impact factor: 3.444

4.  Nitric oxide-NGF mediated PPTA/SP, ADNP, and VIP expression in the peripheral nervous system.

Authors:  Thimmasettappa Thippeswamy; Mark R Howard; Anna Siobhan Cosgrave; Daleep Kumar Arora; Jennifer S McKay; John P Quinn
Journal:  J Mol Neurosci       Date:  2007-09-11       Impact factor: 3.444

5.  Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.

Authors:  Joanna M Hill; Janet M Hauser; Lia M Sheppard; Daniel Abebe; Irit Spivak-Pohis; Michal Kushnir; Iris Deitch; Illana Gozes
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

6.  The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush.

Authors:  T Jehle; C Dimitriu; S Auer; R Knoth; M Vidal-Sanz; I Gozes; W A Lagrèze
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-15       Impact factor: 3.117

Review 7.  Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.

Authors:  Tomohiro Chiba; Ikuo Nishimoto; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590

Review 8.  PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Giuseppe Musumeci; Dora Reglodi; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

Review 9.  Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease.

Authors:  D Farfara; V Lifshitz; D Frenkel
Journal:  J Cell Mol Med       Date:  2008-03-20       Impact factor: 5.310

10.  A Systematic Review of Closed Head Injury Models of Mild Traumatic Brain Injury in Mice and Rats.

Authors:  Colleen N Bodnar; Kelly N Roberts; Emma K Higgins; Adam D Bachstetter
Journal:  J Neurotrauma       Date:  2019-03-06       Impact factor: 5.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.